MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
Study sponsor: Immunic AG
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-04-24Actual
Enrollment · participants210Actual
Source updated2024-04-24Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.